AI Article Synopsis
- The case involves an 84-year-old man with prostatic carcinoma who developed fatal fulminant hepatitis after treatment with cyproterone acetate (CPA).
- Despite negative serological markers for hepatitis and imaging showing gallstones, his condition worsened, leading to the use of an external drain tube.
- The authors emphasize the rarity of CPA-related hepatitis, stressing the importance of closely monitoring liver function in patients on anti-androgenic medications and the need to discontinue CPA if liver function tests show any abnormalities.
Article Abstract
The Authors report a case of prostatic carcinoma in a 84 year old male, treated with cyproterone acetate (CPA), complicated by a fatal fulminant hepatitis. He was admitted with a mixed jaundice followed by a derange of all liver function tests. Serological markers for hepatitis were negative. Ultrasonography and CT revealed no hepatic abnormality but gallstones and dilatation of principal bile duct with a terminal stricture. By the endoscopic retrograde cholangiography and sphincterotomy we put an external drain tube. He died 9 days after admission. Fatal hepatis due to CPA is a very rare complication but all patients on anti-androgenic drugs should have liver function closely monitored. CPA must be discontinued immediately at the first derange of liver function tests.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!